Reuters logo
BRIEF-TG therapeutics provides FDA update on multiple sclerosis study
August 1, 2017 / 11:59 AM / 4 months ago

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

Aug 1 (Reuters) - Tg Therapeutics Inc

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

* Global Phase 3 program expected to commence before end of Q3 2017

* RMS phase 3 program consists of two trials, called Ultimate I and Ultimate II trials Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below